Prostacyclin

References

• Kurzrock R, Lieb CC. Biochemical studies of human semen. II. The action of semen on the human uterus. Proc Soc Exp Biol Med 1930: 28: 268–71
   Google Scholar
• Moncada S, Gryglewski RJ, Bonting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976: 263: 663–5
   PubMed Web of Science ®Google Scholar
• Johnson RA. Morton DR, Kinner JH, et al. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 1976: 12: 915–28
   PubMed Web of Science ®Google Scholar
• Vane JR, Moncada S. Prostacyclin. Ciba Found Symp 1980: 71: 79–97
   PubMedGoogle Scholar
• Vane JR, Moncada S. The anti-thrombotic effects of prostacyclin. Acta Med Scand (Suppl) 1980: 642: 11–22
   Google Scholar
• Bianco S, Robuschi M, Ceserani R, et al. Effects of prostacyclin on aspecifically and speciflcally induced bronchoconstriction in asthmatic patients. Eur J Respir Dis (Suppl) 1980: Suppl 106: 81–7
   Google Scholar
• Fabiana JN, Deloche A. Dubost C. et al. Circulation extracorporelle d'auto-transfusion: utilisation de la prostacyline. Nouvelle Presse Med 1980: 9(28): 1961–2a
   Google Scholar
• Rådegran K, Papaconstantinou C. Prostacyclin infusion during cardiopulmonary bypass in man. Thromb Rea 1980: 19(1–2): 267–70
   PubMed Web of Science ®Google Scholar
• Buntings, O'Grady J, Fabiani JN, et al. Cardiopulmonary bypass in man: effects of prostacyclin. In: Lewis PJ. O'Grady JM. eds. Clinical pharmacology of prostacyclin. New York Raven Press. 1981: 181–93
   Google Scholar
• Walker ID, Davidson JP, Faichncy A, et al. A double-blind study of prostacylin in cardiopulmonary bypass surgery. Br J Haematol 1981: 49(3): 415–23
   PubMed Web of Science ®Google Scholar
• Longmore DB, Bennett JG. Hoyle PH, et al. Prostacyclin administration during cardiopulmonary bypass in man. Lancet 1981: 1(8244): 800–4
   PubMed Web of Science ®Google Scholar
• Heinrich D. Schleussner E. Walter P. et al. Influence of prostacyclin on hemostasls during extra corporeal circulation in aorto-coronary bypass operations. Thorac Cardiovasc Surg 1981: 29(1): 1–54
   Web of Science ®Google Scholar
• Dutton RC. Edmonds LH Jr. Hutchinson JC, et al. Platelet aggregate emboli produced in patients during cardiopulmonary bypass with membrane and bubble oxygenators and blood filters. J Thorac Cardiovasc Surg 1974 Feb: 7: 258–65
   Google Scholar
• Turney JH, Williams LC, Fewell MR. et al. Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet 1980: 2(8188): 219–22
   PubMed Web of Science ®Google Scholar
• Zusman RM, Robin RH, Cato AE, et al. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 1981: 304(16): 934–9
   PubMed Web of Science ®Google Scholar
• Turner JH, Dodd NJ, Weston MJ. Prostacyclin in extracorporeal circulation. (Letter) Lancet 1981: 1 (8229): 1101
   Web of Science ®Google Scholar
• Arse RS, Ward MK. Prostacyclin safer than heparin in haemodialysis. (Letter) Lancet 1981: 2(8236): 50
   Web of Science ®Google Scholar
• Glaser P, Guesde R. Rouby JJ. Haemodialysis without heparin is possible. (Letter) Lancet 1979:2(8142): 579–80
   PubMed Web of Science ®Google Scholar
• Casati S, Ponticelli C. Hemodialysis in patients with a risk of bleeding. (Letter) N Engl J Med 1981: 305(9): 521–2
   PubMed Web of Science ®Google Scholar
• Abuelo JG, Chang BS. Is prostacyclin better than nothing for anticoagulation m haemodialysis? (Letter) Lancet 1981: 2(8244): 470–1
   PubMed Web of Science ®Google Scholar
• Blitser BL. Fulminant hepatic failure: a rare but often lethal coma syndrome Postgrad Med 1980: 68 (3): 153–7, 160–2
   PubMed Web of Science ®Google Scholar
• Gimson AE, Langley PG. Hughes RD, et al. Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet 1980: 1(8161): 173–5
   PubMed Web of Science ®Google Scholar
• Gimson AE, Canalese J, Hughes RD, et al. Charcoal haemoperfusion with prostacyclin in the treatment of fulminant hepatic failure In: Lewis. O'Grady. eds.9 pp 211–8
   Google Scholar
• Silk DB, Williams R. Experiences in the treatment of fulminant hepatic failure by conservative therapy, charcoal haemoperfusion, and polyacrylonitrile haemodialysis. Int J Artif Organs 1978: 1(1): 29–33
   PubMed Web of Science ®Google Scholar
• Szczeklik A. Nizankowaki R, Skawinaki S, et al. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet 1979:1 (8126): 1111–4
   PubMed Web of Science ®Google Scholar
• Olason AG. Intravenous prostacyclin for ischaemic ulcers in peripheral artery disease. (Letter) Lancet 1980: 2(8203): 1076
   Web of Science ®Google Scholar
• Hoasman V. Heinen A. Auel H. et al. A ran domized, placebo controlled trial of prostacyclin (PGI2) in peripheral arterial disease. Thromb Res 1981: 22(4): 481–90
   PubMed Web of Science ®Google Scholar
• Szczeklik A. Gryglewski RJ. Treatment of vascular disease with prostacyclin. In Lewis. O'Grady, eds.9 pp 159–67
   Google Scholar
• Assal JP, Helg C, VonderWeid N. et al. Prostacyclin perfusions in diabetic peripheral arterial insufficiency. Diabetologia 1980: 19(3): 254
   Web of Science ®Google Scholar
• Machin SJ. Defreyn G. Chamone DA. et al. Clinical infusions of prostacyclin in advanced arterial disease. In: Lewis. O'Grady. eds.9 p 173
   Google Scholar
• Dowd PM. Martin MF. Cooke ED, et al. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol 1982: 106(1): 81–9
   PubMed Web of Science ®Google Scholar
• Szczeklik A. Szczeklik J. Nizankowski R. et al. Prostacyclin for acute coronary insufficiency. Artery 1980: 8(1): 7–11
   PubMedGoogle Scholar
• Chierchia S. Crea F. Bernini W. et al. Effects of prostacyclin (PGI2) continuous infusion in angina at rest. Circulation 1980: 2(III): 310
   Google Scholar
• Bergman G. Daly K. Atkinson L. et al. Prostacyclin: haemodynamic and metabolic effects in patients with coronary artery disease. Lancet 1981: 1(8220 Pt 1): 569–72
   PubMed Web of Science ®Google Scholar
• Dargie HJ, Lewis PJ. Effect of prostacyclin on angina at rest. In: Lewis. O'Grady, eds.9 pp 177–80
   Google Scholar
• Hall RJ. Dewar HA. Safety of coronary arterial prostacyclin infusion. (Letter) Lancet 1981: 1(8266): 949
   PubMed Web of Science ®Google Scholar
• Chierchia S. Patrono C, Crea F, et al. Effects of intravenous prostacyclin in variant angina Circulation 1982: 65(3): 470–7
   PubMed Web of Science ®Google Scholar
• Hensby CN, Lewis PJ, Hilgard P. et al. Prostacyclin deficiency in thrombotic thrombocytopenic purpura (Letter) Lancet 1979: 2(8145): 748
   PubMed Web of Science ®Google Scholar
• Budd GT. Bukowski RM. Lucas FV, et al. Prostacyclin therapy of thrombotic thrombocytopenic purpura (Letter) Lancet 1980: 2(8200): 915
   PubMed Web of Science ®Google Scholar
• Fitzgerald GA, Mass RL, Stein R, et al. Intravenous prostacyclin in thrombotic thrombocytopenic purpura. Ann Intern Med 1981: 95(3): 319–22
   PubMed Web of Science ®Google Scholar
• Beattie TJ, Murphy AV. Willoughby ML, et al. Prostacvclin infusion in haemoltic-uraemic syndrome of children. Br Med J (Clin Res) 1981: 283 (6289): 470
   PubMed Web of Science ®Google Scholar
• Webster J, Borysiewicz LK. Rees AJ. et al. Prostacyclin therapy for haemolytic-uraemic syndrome. In: Lewis, O'Grady. eds.9 pp 77–80
   Google Scholar
• Zygulska-Mach H. Kostka-Trabka E. Niton A. et al. Prostacyclin in central retinal vein occlusion. (Letter) Lancet 1980: 2(8203): 1075
   PubMed Web of Science ®Google Scholar
• Watkins WD. Peterson MB, Crone RK. et al. Prostacyclin and prostaglandin E1 for severe Idiopathic pulmonary artery hypertension (Letter) Lancet 1980:1 (8177): 1083
   PubMed Web of Science ®Google Scholar
• Lock JE. Olley PM. Coceani F. et al. Use of prostacyclin in persistent fetal circulation. (Letter) Lancet 1979: 1(8130): 1343
   PubMed Web of Science ®Google Scholar
• Szczeklik J, Szczeklik A. Nizankowski R. Prostacyclin for pulmonary hypertension. (Letter) Lancet 1980: 2(8203): 1076
   PubMed Web of Science ®Google Scholar
• Duadagni DN, Ikram H. Maslowski AH. Haemodynamic effects of prostacyclin (PGI2) in pulmonary hypertension. Br Heart J 1981: 45: 385–8
   PubMedGoogle Scholar
• Fidler J. Ellis C, Bennett MJ, et al. Prostacyclin and preeclamptic toxaemia. In Lewis, O'Grady. eds.9 pp 141–3
   Google Scholar
• Alken JW. Shebuski RJ. Miller OV, et al. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. J Pharmacol Exp Ther 1981: 219(2): 299–308
   PubMed Web of Science ®Google Scholar
• Vennylen J. Chamone DA. Verstraete M. Stimulation of prostacyclin release from vessel wall by BAY g 6575. an antithrombotic compound. Lancet 1979: 1 (8115): 518–20
   PubMed Web of Science ®Google Scholar